| (V818) |
Predictors of 1-year mortality in patients with contemporary optimised guideline-adherent secondary prevention therapy after acute myocardial infarction: results from the OMEGA Study |
|
T. Bauer, R. Schiele, R. Zahn, S. Schneider, B. Rauch, H. Gohlke, G. Sabin, M. G. Gottwik, J. Senges, U. Zeymer (Ludwigshafen, Bad Krozingen, Essen, Nürnberg) |
| (V819) |
Nearly Doubled 5-Year-Mortality in Patients With Stable Coronary Artery Disease and Prior Stroke in Clinical Practice: Results of the STAR-Registry |
|
A. K. Gitt, C. Jünger, A. Papp, F. Towae, J. Senges, R. Zahn für die Studiengruppe STAR (Ludwigshafen) |
| (V820) |
Dosing Clopidogrel Using CYP2C19 Genotypes:The ELEVATE-TIMI 56 Trial |
|
W. Hochholzer, J. L. Mega, A. L. Frelinger, M. J. Kluk, C. T. Ruff, C. Contant, B. M. Scirica, J. A. Longtine, A. D. Michelson, M. S. Sabatine (Bad Krozingen; Boston, US) |
| (V821) |
Indidualized Anti-platelet therapy guided by genotype analysis in patients with acute coronary syndromes |
|
T. Geisler, A. Karathanos, K. Mueller, I. Mueller, F. Stimpfle, B. Bigalke, P. Seizer, M. Gawaz (Tübingen) |
| (V822) |
Impact of Interventional Versus Conservative Approach on 5-Year-Mortality of Patients With Stable Angina and Documented Coronary Artery Disease in Clinical Practice: Results of the STAR-Registry |
|
A. K. Gitt, C. Jünger, A. Papp, F. Towae, R. Zahn, J. Senges für die Studiengruppe STAR (Ludwigshafen) |
| (V823) |
Intracoronary stem cell therapy in patients with acute myocardial infarction – 36 months results of a randomized, double-blind, placebo controlled trial with serial MRI follow-ups |
|
J. Wöhrle, F. von Scheidt, S. Markovic, P. Schauwecker, K. Schwarz, M. Wiesneth, H. Schrezenmeier, V. Hombach, W. Rottbauer, P. Bernhardt (Ulm) |